medigraphic.com
ISSN 2007-2783 (Impreso)
Órgano Oficial del Instituto Científico Pfizer

2015, Número 1

<< Anterior Siguiente >>

Residente 2015; 10 (1)


Lupus eritematoso sistémico: implicaciones de la inmunidad innata

Saucedo-Ulloa M, Contreras-Moreno MG, Saldaña-Anguiano JM, Casillas-Iglesias FI, Rincón-Sánchez A, Lujano-Benítez AV, Corona-Sánchez EG, Martínez-García EA

Idioma: Español
Referencias bibliográficas: 56
Paginas: 4-11
Archivo PDF: 225.06 Kb.


RESUMEN

El lupus eritematoso sistémico es el prototipo de enfermedad autoinmune en la cual los tejidos y las células son dañados por autoanticuerpos y complejos inmunes dirigidos contra componentes del núcleo celular. La etiología del lupus es desconocida, pero existen factores que están relacionados con la presencia de la enfermedad, tal como disregulación del sistema inmune, factores genéticos, hormonales y ambientales. Las alteraciones inmunológicas en el lupus involucran primordialmente a la inmunidad adaptativa. Sin embargo, es importante mencionar que la inmunidad innata también se encuentra implicada con los mecanismos inmunológicos que desarrollan las manifestaciones clínicas del lupus.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Boulé MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and-independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med. 2004; 199 (12): 1631-1640.

  2. Hughes T, Sawalha AH. The role of epigenetic variation in the pathogenesis of systemic lupus erythematosus. Artrhritis Res Ther. 2011; 13 (5): 245.

  3. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003; 21: 335-376.

  4. Rahman A, Isenberg D. Systemic lupus erythematosus. N Engl J Med. 2008; 358: 929-939.

  5. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 20011; 365: 2110-2121.

  6. Rotrosen D, Gallin JI. Disorders of phagocyte function. Ann Rev Immunol. 1987; 5: 127-151.

  7. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis & Rheumatism. 1982; 25 (11): 1271-1277.

  8. Morales-Romero J, Cázares-Mendez JM, Gámez-Nava JI, Triano-Páez M, Villa-Manzano AI, López-Olivo MA et al. Patterns of health care in an outpatient rheumatologic clinic. Reumatol Clin. 2006; 1: 87-94.

  9. Kyttaris VC. Systemic lupus erythematosus: from genes to organ damage. Methods Mol Biol. 2010; 66: 265-283.

  10. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003; 85: 85-95.

  11. Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980; 303: 27-34.

  12. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Ann Rev Immunol. 1994; 12: 593-633.

  13. Demaria O, Di Domizio J, Gilliet M. Immune sensing of nucleic acids in inflammatory skin diseases. Semin Immunopathol. 2014; 36 (5): 519-512.

  14. Jin O, Sun LY, Zhou KX et al. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clin Rheumatol. 2005; 24: 107-110.

  15. Passero FC, Myers AR. Decreased numbers of monocytes in inflammatory exudates in systemic lupus erythematosus. J Rheumatol. 1981; 8: 62-68.

  16. Baumann I, Kolowos W, Voll RE et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002; 46: 191-201.

  17. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998; 41: 1241-1250.

  18. Ren Y, Tang J, Mok MY, Chan AW, Wu A, Lau CS. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum. 2003; 48: 2888-2897.

  19. Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis. 2006; 65: 216-221.

  20. De la Fuente H, Richaud-Patin Y, Jakez-Ocampo J, Gonzalez-Amaro R, Llorente L. Innate immune mechanisms in the pathogenesis of systemic lupus erythematosus (SLE). Immunol Lett. 2001; 77: 175-180.

  21. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994; 152: 3685-3692.

  22. Li Y, Lee PY, Reeves WH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp. 2010; 58: 355-364.

  23. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003; 100: 2610-2615.

  24. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003; 197: 711-723.

  25. Mir A, Porteu F, Levy M, Lesavre P, Halbwachs-Mecarelli L. C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study. Clin Exp Immunol. 1988; 73: 461-466.

  26. Tsai CY, Wu TH, Yu CL, Tsai YY, Chou CT. Decreased IL-12 production by polymorphonuclear leukocytes in patients with active systemic lupus erythematosus. Immunol Invest. 2002; 31: 177-189.

  27. Baxter A. The role of NK cells in autoimmune disease. Autoimmunity. 2002; 35 (1): 1-14.

  28. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994; 152: 3685-3692.

  29. French AR, Yokoyama WM. Natural killer cells and autoimmunity. Arthritis Res Ther. 2004; 6: 8-14.

  30. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56 (bright) subset. Blood. 2001; 97: 3146-3151.

  31. Caligiuri MA. Human natural killer cells. Blood. 2008; 112: 461-469.

  32. Yokoyama WM, Kim S, French AR. The dynamic life of natural killer cells. Annu Rev Immunol. 2004; 22: 405-429.

  33. Ewan PW, Barrett HM, Pusey CD. Defective natural killer (NK) and killer (K) cell function in systemic lupus erythematosus. J Clin Laboratory Immunol. 1983; 10: 71-76.

  34. Sibbitt WL Jr, Mathews PM, Bankhurst AD. Natural killer cell in systemic lupus erythematosus. Defects in effector lytic activity and response to interferon and interferon inducers. J Clin Invest. 1983; 71: 1230-1239.

  35. Jawahar S, Moody C, Chan M, Finberg R, Geha R, Chatila T. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin Exp Immunol. 1996; 103: 408-413.

  36. Park YW, Kee SJ, Cho YN, Lee EH, Lee HY, Kim EM et al. Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum. 2009; 60: 1753-1763.

  37. Tao D, Shangwu L, Qun W et al. CD226 expression deficiency causes high sensitivity to apoptosis in NK T cells from patients with systemic lupus erythematosus. J Immunol. 2005; 174: 1281-12890.

  38. Huang Z, Fu B, Zheng SG, Li X, Sun R, Tian Z et al. Involvement of CD226 NK cells in immunopathogenesis of systemic lupus erythematosus. J Immunol. 2011; 186: 3421-3431.

  39. Carroll MC. A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol. 2004; 4: 825-831.

  40. Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006; 65: 57-63.

  41. Botto M, Kirschfink M, Macor P, Pickering MC, Wurzner R, Tedesco F. Complement in human diseases: lessons from complement deficiencies. Mol Immunol. 2009; 46: 2774-2783.

  42. Pickering MC, Walport MJ. Links between complement abnormalities and systemic lupus erythematosus. Rheumatology. 2000; 39: 133-141, (Oxford).

  43. Abel G, Agnello V. Complement deficiencies: a 2004 update. In: Szebeni J. (Ed). The complement system. Novel roles in health and disease. Boston: Kluwer Academic Publishers; 2004. pp. 201-228.

  44. O’Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev. 2008; 226: 10-18.

  45. Christensen SR et al. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med. 2005; 202: 321–331.

  46. Yu P et al. Toll-like receptor 9 in murine lupus: more friend than foe. Immunobiology. 2008; 213: 151–157.

  47. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010; 11: 373-384.

  48. Christensen SR, Shlomchik MJ. Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Seminars in Immunology. 2007; 19: 11-23.

  49. Xu CJ, Zhang WH, Pan HF, Li XP, Xu JH, Ye DQ. Association study of a single nucleotide polymorhism in the exon 2 region of toll-like receptor 9 (TLR9) gene with susceptibility to systemic lupus erythematosus among Chinese. Mol Biol Rep. 2009; 36 (8): 2245-2248.

  50. Zhou XJ, Lv JC, Cheng WR, Yu L, Zhao MH, Zhang H. Association of TLR9 gene polymorphism with lupus nephritis in a Chinese Han population. Clin Exp Rheumatol. 2010; 28 (3): 397-400.

  51. Roszak A, Lianeri M, Sowinska A, Jagodzinski PP. Involvement of toll-like receptor 9 polymorphism in cervical cancer development. Mol Biol Rep. 2012; 39: 8425-8430.

  52. Dos Santos BP, Valverde JV, Rohr P, Monticielo OA, Brenol JC, Xavier RM et al. TLR7/8/9 polymorphism and their associations in systemic lupus erythematosus patients from southern Brazil. Lupus. 2012; 21 (3): 302-309.

  53. Kahlenberg JM, Kaplan MJ. The inflammasome and lupus: another innate immune mechanism contributing to disease pathogenesis? Curr Opin Rheumatol. 2014 Sep;26(5):475-81. doi: 10.1097/BOR.0000000000000088. PubMed PMID: 24992143; PubMed Central PMCID: PMC4153426.

  54. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005 May;52(5):1491-503. PubMed PMID: 15880830.

  55. Smith PL, Lombardi G, Foster GR. Type I interferons and the innate immune response--more than just antiviral cytokines. Mol Immunol. 2005 May;42(8):869-77. Epub 2005 Jan 13. Review. PubMed PMID: 15829276.

  56. Yao Y, Richman L, Higgs BW, Morehouse CA, de los Reyes M, Brohawn P, Zhang J, White B, Coyle AJ, Kiener PA, Jallal B. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009 Jun;60(6):1785-96. doi: 10.1002/art.24557. PubMed PMID: 19479852.




2020     |     www.medigraphic.com